A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Research summary

This is a Phase 2, nonrandomized, single-arm, multisite, open-label study of the PK, efficacy, and safety of MK-3475A SC in adult participants with rrcHL or rrPMBCL. Participants must be anti-PD-1 and anti-PD-L1/PD-L2 naïve. Participants with rrcHL (Cohort 1) must have failed to respond or relapsed after at least 1 line of multiagent therapy (chemotherapy with or without BV), or did not achieve CR or relapsed after an auto-SCT, or are ineligible for auto-SCT. Participants with rrPMBCL (Cohort 2) must have failed to respond or relapsed after ≥ 2 lines of prior therapy, or did not achieve CR or relapsed after auto-SCT or are ineligible for auto-SCT. At least 1 of the prior lines of therapy must contain a rituximab based regimen. Participants with rrPMBCL must not require urgent cytoreductive therapy.

Principal Investigator

Dr Graham Collins

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1010002